Breaking News Instant updates and real-time market news.

2016-11-28 08:34:04

FOMX

Foamix

$9.36

0.14 (1.52%)

08:34

11/28/16

11/28

08:34

11/28/16

08:34

Foamix completes enrollment of patients in Phase 3 trials for FMX101

Foamix Pharmaceuticals announced that it has completed patient enrollment according to plan in the company's two Phase 3 clinical trials to evaluate the efficacy and safety of FMX101, a topical 4% minocycline foam, in the treatment of moderate-to-severe acne. Foamix is conducting the two Phase 3 pivotal trials simultaneously, and expects to report top-line results in the first half of 2017. A total of 961 patients with moderate-to-severe acne were enrolled between the two trials.

FOMXFoamix

$9.36

0.14 (1.52%)

12/03/15

COWN

12/03/15NO CHANGECOWNOutperform

Foamix reports strong FMX101 data, says Cowen

Cowen said Foamix reported strong FMX101 data and believes it will be replicated in Phase III. The firm's consultants believe the platform is exceedingly compelling and Cowen's $30 price target could be overly conservative. Cowen rates Foamix shares an Outperform.